Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.57 |
| ▸ | HTR1A | P08908 | 7/20 | 0.57 |
| ▸ | HTR2C | P28335 | 8/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822134 | 0.89 | HTR3A (0.49) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL1273995 | 0.86 | HTR2A (0.48) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL3962252 | 0.84 | HTR2C (0.60) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL1765134 | 0.82 | HTR2C (0.61) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL30952434 | 0.82 | HTR2C (0.61) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL28247586 | 0.82 | HTR2A (0.46) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL24120164 | 0.81 | HTR2C (0.69) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL17229875 | 0.81 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL30896675 | 0.81 | HTR2C (0.50) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL26374821 | 0.81 | HTR2C (0.69) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
| WO-2019115586-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2019-06-20 | — | — | WO | disclosed |
| EP-2864331-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL MYERS SQUIBB CO (US) | 2017-08-09 | — | — | EP | disclosed |
| US-9682980-B2 | Positive allosteric modulators of mGluR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-20 | — | — | US | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150152113-A1 | Positive Allosteric Modulators of MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-04 | — | — | US | disclosed |
| EP-2864331-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | Bristol-Myers Squibb Company (US) | 2015-04-29 | — | — | EP | disclosed |
| WO-2013192306-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-27 | — | — | WO | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| EP-1768958-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-04-04 | — | — | EP | disclosed |
| EP-1765779-A1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| WO-2005121088-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121092-A1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | SLC6A2 1396/4885SLC6A4 876/4885SLC6A3 1605/4885 |
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | SLC6A2 21/4885SLC6A4 10/4885SLC6A3 23/4885 |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | DRD2, AVPR2, NTSR2 | SLC6A2 49/4885SLC6A4 210/4885SLC6A3 8/4885 |
| US-20150152113-A1 | Positive Allosteric Modulators of MGLUR2 | GRM2, GRM1, GRIN2A | SLC6A2 355/4885SLC6A4 426/4885SLC6A3 274/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | SLC6A2 21/4885SLC6A4 10/4885SLC6A3 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.